Intimation for Re-appointment of Directors retiring by rotation.
ANUHPHR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Anuh Pharma's Board meeting on May 20, 2026 approved multiple items including audited FY2026 results showing revenue of Rs. 7,717 lakh (up 16.6% from Rs. 6,615 lakh), but profit after tax declined to Rs. 410 lakh from Rs. 474 lakh in FY2025. The Board recommended a dividend of Rs. 1.50 per share (30% on Rs. 5 face value), subject to shareholder approval at the AGM on August 12, 2026. Two non-executive directors (Mr. Bipin Shah and Mr. Arun Todarwal) were re-appointed as directors retiring by rotation, pending AGM approval. Nine promoter group members (holding 0.95% stake) sought re-classification from Promoter Group to Public category. New appointments included Mr. P.N. Rao as General Manager - Quality and RMJ & Associates LLP as Internal Auditors for FY2026-27.
The profit decline despite revenue growth and rising inventory levels may concern investors. The promoter re-classification requests (0.95% stake) signal potential reduction in promoter holding. The dividend declaration and director re-appointments are routine governance matters with minimal direct market impact.